Cargando…

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer

PURPOSE: The independent predictive information from progesterone receptor (PgR) positivity for breast cancer treated with tamoxifen has been questioned after an overview by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). However, the studies in the overview were to a large content...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nordenskjöld, Anna, Fohlin, Helena, Fornander, Tommy, Löfdahl, Britta, Skoog, Lambert, Stål, Olle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2016
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065613/ https://www.ncbi.nlm.nih.gov/pubmed/27722840 http://dx.doi.org/10.1007/s10549-016-4007-5

Ejemplares similares

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
por: Fohlin, Helena, et al.
Publicado: (2020)

RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer
por: Fohlin, Helena, et al.
Publicado: (2020)

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
por: Bostner, Josefine, et al.
Publicado: (2012)

17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer
por: Sivik, Tove, et al.
Publicado: (2012)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
por: Jerevall, Piiha-Lotta, et al.
Publicado: (2010)

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer
por: Weiner, M., et al.
Publicado: (2013)

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer
por: Hilborn, Erik, et al.
Publicado: (2016)

Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial
por: Dar, Huma, et al.
Publicado: (2021)

Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
por: Nordenskjöld, Anna, et al.
Publicado: (2023)

C–X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients
por: Hilborn, Erik, et al.
Publicado: (2014)

Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer
por: Johansson, Henrik J, et al.
Publicado: (2015)

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
por: Wegman, Pia, et al.
Publicado: (2005)

Survival Benefit of Tamoxifen in Estrogen Receptor-Negative and Progesterone Receptor-Positive Low Grade Breast Cancer Patients
por: Yang, Li-Heng, et al.
Publicado: (2012)

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk
por: van ‘t Veer, Laura J., et al.
Publicado: (2017)

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature
por: Johansson, Annelie, et al.
Publicado: (2022)

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials
por: Karlsson, Elin, et al.
Publicado: (2013)

HORMONET: a phase II trial of tamoxifen for estrogen/progesterone receptor-positive neuroendocrine tumors
por: Barros, Milton J., et al.
Publicado: (2023)

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
por: Schroeder, Brock, et al.
Publicado: (2017)

Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer
por: Sheri, A., et al.
Publicado: (2017)

High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer
por: Paulsson, Janna, et al.
Publicado: (2016)

A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer
por: Takada, Masahiro, et al.
Publicado: (2023)

The rate of estrogen receptor‐conversion associated with tumor progression in estrogen receptor‐positive breast cancer patients following adjuvant Tamoxifen administration
por: Djahansouzi, Sirus, et al.
Publicado: (2021)

Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor‐Positive/Androgen Receptor‐Positive Advanced Breast Cancer
por: Lu, Qianyi, et al.
Publicado: (2019)

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
por: Rosell, J, et al.
Publicado: (2011)

Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer
por: Chan, Melissa, et al.
Publicado: (2015)

Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
por: Iwata, Hiroji, et al.
Publicado: (2023)

Akt kinases in breast cancer and the results of adjuvant therapy
por: Stål, Olle, et al.
Publicado: (2003)

Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer
por: Walter, Vincent, et al.
Publicado: (2020)

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
por: Sasada, Shinsuke, et al.
Publicado: (2023)

Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
por: Alkner, S., et al.
Publicado: (2017)

PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer
por: Karlsson, Elin, et al.
Publicado: (2018)

The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients
por: Stemmer, Salomon M., et al.
Publicado: (2013)

Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer
por: Zhao, Shen, et al.
Publicado: (2019)

Influence of Tamoxifen‐Medroxyprogesterone Sequential Therapy on Estrogen and Progesterone Receptor Contents of Breast Cancer
por: Noguchi, Shinzaburo, et al.
Publicado: (1989)

Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer
por: Lee, Eun-Shin, et al.
Publicado: (2016)

Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype
por: Hefti, Marco M, et al.
Publicado: (2013)

Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma
por: Bièche, Ivan, et al.
Publicado: (2004)

Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells
por: Gao, Pin, et al.
Publicado: (2018)

Effects of low-dose tamoxifen on breast cancer biomarkers Ki-67, estrogen and progesterone receptors
por: de Sousa, Juarez Antônio, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_e1r6s36esllttrn51mc2tjdo9b